Navigation Links
HPV Test Beats Pap Smear in Gauging Cervical Cancer Risk, Study Finds
Date:7/21/2014

FRIDAY, July 18, 2014 (HealthDay News) -- A new study involving data on more than 1 million women finds the HPV test outperforming the standard Pap test in assessing cervical cancer risk.

Researchers at the U.S. National Cancer Institute (NCI) conclude that a negative test for HPV (human papillomavirus) infection is associated with an extremely low risk for cervical cancer and provides greater assurance of low cervical cancer risk than a negative Pap test.

Sexually transmitted HPV infection is thought to cause the majority of cervical cancers.

The findings support current guidelines that advise that both tests be used in cervical cancer screening, study lead author Julia Gage, a research fellow in the NCI's division of cancer epidemiology and genetics, said in an institute news release.

She believes the findings also bolster support for use of the HPV test alone "as another alternative for cervical screening."

As the experts explained it, certain types of HPV cause nearly all cervical cancers. A Pap test detects abnormal cell changes associated with cervical cancer, and both the Pap and the HPV test involve the use of cells collected from the cervix.

The new study included women aged 30 to 64 in California who underwent HPV and Pap testing between 2003 and 2012.

The risk of developing cervical cancer within three years after a negative HPV test was about half the already low risk seen after a negative Pap test, the study found.

The number of women who developed cervical cancer within three years was 11 per 100,000 after a negative HPV test compared to 20 per 100,000 after a negative Pap test, the investigators found.

One expert welcomed the new study.

Dr. Jill Maura Rabin works in Women's Health Programs-PCAP Services at North Shore-LIJ Health System in New Hyde Park, N.Y. She said the finding "provides greater assurance regarding future risk of cervical cancer."

She believes that "the annual well-woman visit remains an excellent venue to re-assess your health and risk status, to evaluate your complete health as well as to address any concerns you may have."

However, a negative HPV test does not mean that a woman is risk-free for life, Rabin stressed. "The risk of HPV and other sexually transmitted infections remains a factor should your risk status change -- for example, a new partner, or any illness which suppresses your immune system," she said.

The study was published online July 18 in the Journal of the National Cancer Institute.

The U.S. Preventive Services Task Force, an influential advisory group, currently recommends Pap testing every three years between the ages 21 to 65, or co-testing every five years between the ages 30 to 65 for women with normal screening results.

More information

The U.S. Centers for Disease Control and Prevention has more about cervical cancer screening.

SOURCES: Jill Maura Rabin, M.D., co-chief, division of ambulatory care, Women's Health Programs-PCAP Services, North Shore-LIJ Health System, New Hyde Park, N.Y.; U.S. National Cancer Institute, news release, July 18, 2014

--


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Medicare Beats Private Plans for Patient Satisfaction: Survey
2. HPV Test Beats Pap Long-Term: Study
3. Bypass Beats Stents for Diabetic Heart Patients: Study
4. Botox beats steroids for painful foot condition, plantar fasciitis
5. For Early Cancer, Lumpectomy Beats Mastectomy for Survival: Study
6. New Blood Thinner Beats Older Drug for Vein Clots: Study
7. Symptoms and care of irregular heartbeats differ by gender
8. iGear's Slim Tough Case Protects iPhone from 20ft Drop and Beats Otterbox in Protection
9. Top-Ranked Golfer Beats Scoliosis
10. Gonzales Resident Beats the Odds and Reunites with Acadian Ambulance Paramedic
11. Bariatric surgery beats medical therapy alone for managing diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HPV Test Beats Pap Smear in Gauging Cervical Cancer Risk, Study Finds
(Date:8/22/2017)... Marina del Rey, CA (PRWEB) , ... August ... ... provider of revenue cycle management (RCM) solutions, announced recently the availability of a ... the HIM community in appreciation for their service to the healthcare industry. E/M ...
(Date:8/22/2017)... , ... August 22, 2017 , ... “To Walk Away”: ... on a B17 bomber named Edward Koontz. “To Walk Away” is the creation of ... who has published over two hundred manuscripts in chemistry and religion, as well as ...
(Date:8/22/2017)... ... , ... “Covert Awakening”: Walid’s spiritual journey from Islamic terrorist ... a consultant for the Intelligence Community. For more than ten years, she ... region. Julianne has written hundreds of reports for the US government analyzing ...
(Date:8/22/2017)... ... ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, a leader ... modern life continually makes more demands on time and energy, people are finding it ... in vicious high/low cycles and can also cause long term health issues. More people ...
(Date:8/21/2017)... ... 22, 2017 , ... PracticeMatch, a company that provides online resources , ... and advanced practitioners like nurse practitioners and physician assistants , will ... of this year. The online career fairs will allow job seekers to connect with ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
(Date:7/26/2017)... 26, 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) ... trial evaluating Altemia TM , an oral therapy for ... Cell Disease (SCD). The SCOT Trial, is a double-blind, ... safety of Altemia TM in pediatric patients aged ... IND 125274. "The ...
Breaking Medicine Technology: